Santambrogio Roberto, Chiang Jason, Barabino Matteo, Meloni Franca Maria, Bertolini Emanuela, Melchiorre Fabio, Opocher Enrico
UOC di Chirurgia Epato-bilio-pancreatica e Digestiva, Ospedale San Paolo, Università di Milano, Milan, Italy.
Department of Radiology, University of Wisconsin, Madison, WI, USA.
Ann Surg Oncol. 2017 Jan;24(1):257-263. doi: 10.1245/s10434-016-5527-2. Epub 2016 Aug 31.
Laparoscopic thermal ablation is a common alternative to surgical resection in treating hepatic tumors, particularly in those located in difficult-to-reach locations.
The aim of this study was to compare the safety and long-term efficacy of laparoscopic radiofrequency ablation (RFA) and microwave ablation (MWA) in treating hepatocellular carcinoma (HCC).
From February 2009 to May 2015, data from patients with HCC nodules who had undergone either laparoscopic MWA or laparoscopic RFA were examined. Complications, complete ablation rates, local tumor progression (LTP) rates, and disease-free and cumulative survival rates were compared between the two treatment groups.
A total of 154 patients with HCC (60 MWA and 94 RFA) were treated via the laparoscopic approach. Major complication rates were identified as 1 and 2 % in the RFA and MWA groups, respectively (p = 0.747). Complete ablation rates were 95 % for both treatment groups (p = 0.931), and LTP rates were 21.2 % for RFA and 8.3 % for MWA (p = 0.034). Disease-free survival rates at 5 years were 19 % in the RFA group and 12 % in the MWA group (p = 0.434), while cumulative survival rates at 5 years were 50 % in the RFA group and 37 % in the MWA group (p = 0.185).
Laparoscopic RFA and MWA appear to be safe in the treatment of early-stage HCC. The LTP rates were lower in the laparoscopic MWA group compared with the laparoscopic RFA group, but their respective overall and disease-free survival rates remained similar.
腹腔镜热消融是治疗肝肿瘤的一种常见手术切除替代方法,尤其是对于位于难以触及部位的肿瘤。
本研究旨在比较腹腔镜射频消融(RFA)和微波消融(MWA)治疗肝细胞癌(HCC)的安全性和长期疗效。
回顾性分析2009年2月至2015年5月期间接受腹腔镜MWA或腹腔镜RFA治疗的HCC结节患者的数据。比较两组的并发症、完全消融率、局部肿瘤进展(LTP)率、无病生存率和累积生存率。
共有154例HCC患者(60例行MWA,94例行RFA)接受了腹腔镜治疗。RFA组和MWA组的主要并发症发生率分别为1%和2%(p = 0.747)。两组的完全消融率均为95%(p = 0.931),RFA组的LTP率为21.2%,MWA组为8.3%(p = 0.034)。RFA组5年无病生存率为19%,MWA组为12%(p = 0.434);RFA组5年累积生存率为50%,MWA组为37%(p = 0.185)。
腹腔镜RFA和MWA治疗早期HCC似乎是安全的。腹腔镜MWA组的LTP率低于腹腔镜RFA组,但其总体生存率和无病生存率相似。